Makers Laboratories Ltd.
NSE: MAKERSL · Pharmaceuticals · sector
₹185.72NSE close 2026-10-26
Key numbers
Market cap₹110 cr
Price₹185.72
52w high / low₹236 / ₹150
P/E30.0xSector median 27.9x
P/B1.5xSector median 2.9x
Book value₹123.6
Dividend yield–Sector median 0.48%
ROE4.8%Sector median 11.7%
ROCE20.9%Sector median 12.3%
OPM12.6%Sector median 14.0%
Debt / equity0.07xSector median 0.16x
EV/EBITDA5.5xSector median 18.6x
Interest cover21.9x
Current ratio2.56x
Sales growth 3y+48.9%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹12 cr vs borrowings ₹5 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 21.9x in the last 12 months.
- Net loss in 2 of the last 6 quarters.
- Other income was 60% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹185.72 on 2026-10-26: -21.3% from the 52-week high, +23.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹214.49 · low ₹113.25
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 34 | 35 | 34 | 36 | 36 | 43 |
| EBITDA | 3 | 3 | 2 | 4 | 5 | 7 |
| OPM % | 9.1% | 8.6% | 6.7% | 11.7% | 14.7% | 16.3% |
| Other income | 0 | 0 | 0 | 0 | 1 | 1 |
| Net profit | -0 | 0 | -0 | 1 | 1 | 2 |
| EPS (₹) | 0.08 | 0.74 | 0.20 | 1.59 | 1.85 | 2.55 |
| Revenue YoY | +5.5% | +22.2% | ||||
| Profit YoY | – | +240.9% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 52 | 43 | 49 | 121 | 141 | 148 |
| EBITDA | 3 | -4 | -4 | 8 | 15 | 19 |
| Net profit | 0 | -6 | -7 | 7 | 2 | 3 |
| EPS (₹) | 0.35 | -10.58 | -11.78 | 12.70 | 3.99 | 6.19 |
| Revenue growth | -18.8% | +15.4% | +146.0% | +16.4% | – | |
| Profit growth | -3,841.2% | – | – | -68.6% | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +48.9% | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 71 | 73 |
| Borrowings | 3 | 5 |
| Cash & equivalents | 1 | 12 |
| Total assets | 148 | 167 |
| Fixed assets | 73 | 70 |
| Capital work in progress | 1 | 4 |
| Investments | 0 | 0 |
| Receivables | 28 | 20 |
| Inventory | 34 | 45 |
| Payables | 12 | 20 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -4 | 14 |
| Cash from investing | 20 | -15 |
| Cash from financing | -16 | 0 |
| Capex | 4 | 4 |
| Free cash flow | -8 | 11 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 10.6% | 3.2% |
| ROCE % | 19.9% | 15.3% |
| Debtor days | 84 | 52 |
| Inventory days | 230 | 250 |
| Payable days | 79 | 110 |
| Cash conversion cycle (days) | 235 | 192 |
| Working capital days | 142 | 137 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| MAKERSL | ₹110 cr | 30.0x | 1.5x | 4.8% | 20.9% | 12.6% | +48.9% | – |
Business segments (2026-06-30)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Chemical Manufacturing | ₹33 cr | 76.4% | ₹8 cr | 22.8% |
| Pharmaceutical | ₹10 cr | 23.6% | ₹-1 cr | -12.3% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2019-08-01 | Dividend | Final Dividend Rs 1.0 |
| 2018-07-26 | Dividend | Dividend Rs 1.0 |
| 2017-07-20 | Dividend | Dividend Rs 1.0 |
| 2016-08-02 | Dividend | Dividend Rs 1.0 |
| 2015-07-28 | Dividend | Dividend Rs 1.0 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | MAKERSL |
| BSE code | 506919 |
| ISIN | INE987A01010 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = NSE close 2026-10-26.